Publication | Closed Access
Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment
688
Citations
29
References
2000
Year
In this re-treatment population, safety and efficacy were not apparently different from those after initial rituximab exposure.
| Year | Citations | |
|---|---|---|
Page 1
Page 1